Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Purple Biotech (PPBT) Stock Price & Analysis

PPBT Stock Chart & Stats

$1.17$0.08(7.34%)
At close: 4:00 PM EDT
$1$1.5$23 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
$1.07 - $1.17
52-Week Range
$0.91 - $9.10
Previous Close
$1.09
Volume
11.51K
Average Volume (3M)
25.17K
Market Cap
$10.31M
Enterprise Value
-$4.20M
Total Cash (Recent Filing)
$6.11M
Total Debt (Recent Filing)
$134.00K
Price to Earnings (P/E)
―
Beta
0.77
Next Earnings
Nov 13, 2026 (Est.)
EPS Estimate
-2.88
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Very low leverage reduces refinancing and solvency pressure while preserving flexibility to allocate resources toward clinical development. Although the company is not yet profitable, limited debt means less cash is diverted to interest and principal obligations during its development phase.

Strengthening Oncology IP

Expanded U.S. patent protection strengthens the defensibility of CAPTN-3 and can improve the company’s position in future partnering discussions. A broader intellectual-property estate may support development and commercialization of multiple oncology programs rather than a single asset.

Differentiated Immunotherapy Platform

Preclinical evidence across safety, durability, therapeutic window, and treatment-resistant tumors supports a differentiated scientific proposition for IM1240. If these findings translate clinically, the platform could address unmet needs in solid tumors and create partnering or development opportunities.

Bears Say

Minimal Revenue And Persistent Losses

The absence of meaningful revenue leaves PPBT dependent on research progress and future financing rather than recurring commercial income. Persistent sizable losses also show that current operations do not yet support the cost of advancing the pipeline, delaying any clear path to self-funded growth.

Ongoing Cash Burn

Negative operating and free cash flow indicate that PPBT continues to consume cash to fund development and cannot presently finance operations internally. Even with a moderated burn rate, continued dependence on external funding remains important until revenue scales or losses narrow.

Eroded Equity Base

The sharp reduction in shareholders’ equity demonstrates that cumulative losses have materially weakened the capital base. If additional financing is needed to sustain clinical programs, continued erosion may constrain strategic flexibility and could increase the risk of dilution for existing shareholders.

Purple Biotech News

PPBT FAQ

What was Purple Biotech’s price range in the past 12 months?
Purple Biotech lowest stock price was $0.91 and its highest was $9.10 in the past 12 months.
What is Purple Biotech’s market cap?
Purple Biotech’s market cap is $10.31M.
When is Purple Biotech’s upcoming earnings report date?
Purple Biotech’s next earnings report is estimated for Nov 13, 2026 (not yet confirmed), which is in 12 days.
How were Purple Biotech’s earnings last quarter?
Purple Biotech released its earnings results on Aug 07, 2026. The company reported -$0.41 earnings per share for the quarter, beating the consensus estimate of -$0.98 by $0.57.
Is Purple Biotech overvalued?
According to Wall Street analysts Purple Biotech’s price is currently Undervalued.
Does Purple Biotech pay dividends?
Purple Biotech does not currently pay dividends.
What is Purple Biotech’s EPS estimate?
Purple Biotech’s EPS estimate is -2.88.
How many shares outstanding does Purple Biotech have?
Purple Biotech has 1,620,982 shares outstanding.
What happened to Purple Biotech’s price movement after its last earnings report?
Purple Biotech reported an EPS of -$0.41 in its last earnings report, beating expectations of -$0.98. Following the earnings report the stock price went up 1.418%.
Which hedge fund is a major shareholder of Purple Biotech?
Currently, no hedge funds are holding shares in PPBT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology